Technical Analysis for IXC - Invex Therapeutics Ltd
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Expansion Breakout | Bullish Swing Setup | 0.00% | |
| Jack-in-the-Box Bullish | Bullish Swing Setup | 0.00% | |
| Volume Surge | Other | 0.00% | |
| Above Upper BB | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Expansion Breakout | Bullish Swing Setup | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Volume Surge | Other | 0.00% | |
| Above Upper BB | Strength | 0.00% |
| Alert | Time |
|---|---|
| Gap Down Closed | 5 days ago |
| Reversed from Down | 5 days ago |
| Gapped Down (Full) | 5 days ago |
| Down 1 ATR | 5 days ago |
| 10x Volume Pace | 5 days ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
Invex Therapeutics Ltd Australia-based biopharmaceutical company that focuses on research and development of treatments for neurological conditions. The Company’s Exenatide is a glucagon-like peptide-1 receptor agonist approved for the treatment of type II diabetes. It also focuses on reformulating Exenatide to deliver it in a way that enables exploitation of its previously unknown ability to reduce cerebral spinal fluid secretion in the choroid plexus of the brain. The Company intends to progress expediently to clinical evaluation and undertake the registration of different formulations of Exenatide optimised to treat different neurological conditions.
Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Flu Biopharmaceutical Progress Diabetes Organ Systems Peptide Endocrine System Expedient I Diabetes Ii Diabetes
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Flu Biopharmaceutical Progress Diabetes Organ Systems Peptide Endocrine System Expedient I Diabetes Ii Diabetes
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 0.34 |
| 52 Week Low | 0.06 |
| Average Volume | 42,675 |
| 200-Day Moving Average | 0.113 |
| 50-Day Moving Average | 0.073 |
| 20-Day Moving Average | 0.079 |
| 10-Day Moving Average | 0.083 |
| Average True Range | 0.004 |
| RSI (14) | 63.37 |
| ADX | 18.92 |
| +DI | 46.458 |
| -DI | 20.625 |
| Chandelier Exit (Long, 3 ATRs) | 0.080 |
| Chandelier Exit (Short, 3 ATRs) | 0.081 |
| Upper Bollinger Bands | 0.090 |
| Lower Bollinger Band | 0.068 |
| Percent B (%b) | 1.01 |
| BandWidth | 28.244 |
| MACD Line | 0.004 |
| MACD Signal Line | 0.003 |
| MACD Histogram | 0.001 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.098 | ||||
| Resistance 3 (R3) | 0.097 | 0.093 | 0.096 | ||
| Resistance 2 (R2) | 0.093 | 0.091 | 0.094 | 0.096 | |
| Resistance 1 (R1) | 0.092 | 0.090 | 0.093 | 0.093 | 0.095 |
| Pivot Point | 0.088 | 0.088 | 0.089 | 0.089 | 0.088 |
| Support 1 (S1) | 0.087 | 0.086 | 0.088 | 0.088 | 0.085 |
| Support 2 (S2) | 0.083 | 0.085 | 0.084 | 0.084 | |
| Support 3 (S3) | 0.082 | 0.083 | 0.084 | ||
| Support 4 (S4) | 0.083 |
